Sabra Health Care REIT, Inc. (SBRA)
NASDAQ: SBRA · Real-Time Price · USD
18.29
+0.26 (1.44%)
At close: Aug 1, 2025, 4:00 PM
18.14
-0.15 (-0.82%)
After-hours: Aug 1, 2025, 7:26 PM EDT
Chimerix Stock Forecast
Stock Price Forecast
The 7 analysts that cover Chimerix stock have a consensus rating of "Buy" and an average price target of $19.71, which forecasts a 7.76% increase in the stock price over the next year. The lowest target is $18 and the highest is $20.
Price Target: $19.71 (+7.76%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 23, 2025.
Analyst Ratings
The average analyst rating for Chimerix stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Hold Maintains $19 → $20 | Hold | Maintains | $19 → $20 | +9.35% | Jun 23, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $18 → $19 | Hold | Maintains | $18 → $19 | +3.88% | May 12, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | -1.59% | Mar 18, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $20 | Buy | Reiterates | $20 | +9.35% | Feb 21, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $18 → $17 | Strong Buy → Hold | Downgrades | $18 → $17 | -7.05% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
747.17M
from 702.64M
Increased by 6.34%
Revenue Next Year
800.42M
from 747.17M
Increased by 7.13%
EPS This Year
0.72
from 0.54
Increased by 33.17%
EPS Next Year
0.78
from 0.72
Increased by 8.98%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 821.0M | 992.7M | 1.1B | ||
| Avg | 747.2M | 800.4M | 889.4M | ||
| Low | 692.3M | 716.3M | 734.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.8% | 32.9% | 43.2% | ||
| Avg | 6.3% | 7.1% | 11.1% | ||
| Low | -1.5% | -4.1% | -8.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.80 | 0.88 | 0.88 |
| Avg | 0.72 | 0.78 | 0.82 |
| Low | 0.67 | 0.72 | 0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 47.8% | 22.7% | 12.5% |
| Avg | 33.2% | 9.0% | 4.6% |
| Low | 23.4% | -0.5% | -6.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.